Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings.
The global Anti-Venom market is projected to grow from US$ 1002.9 million in 2024 to US$ 1283.7 million by 2030, at a Compound Annual Growth Rate (CAGR) of 4.2% during the forecast period.
CSL is the world leading manufacturer in global Anti-Venom market with the market share of 27%, in terms of revenue, followed by Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech and MicroPharm. These 11 companies accounted for 68% of the revenue market share in 2019. Asia-Pacific, Middle East and Africa are the largest consumption regions, occupied about 77% of market share, in terms of volume. The application of Anti-Venom in hospital and clinics take the main global shares. The polyvalent Anti-Venom takes more global revenue shares compared to the Monovalent Anti-Venom, which accounts for 67% in 2019.
Report Covers:
This report presents an overview of global market for Anti-Venom, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Anti-Venom, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Anti-Venom, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Anti-Venom sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Anti-Venom market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Anti-Venom sales, projected growth trends, production technology, application and end-user industry.
麻豆原创 Segmentation
By Company
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm
Segment by Type
Polyvalent Anti-Venom
Monovalent Anti-Venom
Segment by Application
Non-profit Institutions
Hospitals and Clinic
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Anti-Venom in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Anti-Venom manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-Venom sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Study Coverage
1.1 Anti-Venom Product Introduction
1.2 麻豆原创 by Type
1.2.1 Global Anti-Venom 麻豆原创 Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Polyvalent Anti-Venom
1.2.3 Monovalent Anti-Venom
1.3 麻豆原创 by Application
1.3.1 Global Anti-Venom 麻豆原创 Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Non-profit Institutions
1.3.3 Hospitals and Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Anti-Venom Sales Estimates and Forecasts 2019-2030
2.2 Global Anti-Venom Revenue by Region
2.2.1 Global Anti-Venom Revenue by Region: 2019 VS 2023 VS 2030
2.2.2 Global Anti-Venom Revenue by Region (2019-2024)
2.2.3 Global Anti-Venom Revenue by Region (2025-2030)
2.2.4 Global Anti-Venom Revenue 麻豆原创 Share by Region (2019-2030)
2.3 Global Anti-Venom Sales Estimates and Forecasts 2019-2030
2.4 Global Anti-Venom Sales by Region
2.4.1 Global Anti-Venom Sales by Region: 2019 VS 2023 VS 2030
2.4.2 Global Anti-Venom Sales by Region (2019-2024)
2.4.3 Global Anti-Venom Sales by Region (2025-2030)
2.4.4 Global Anti-Venom Sales 麻豆原创 Share by Region (2019-2030)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Anti-Venom Sales by Manufacturers
3.1.1 Global Anti-Venom Sales by Manufacturers (2019-2024)
3.1.2 Global Anti-Venom Sales 麻豆原创 Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Anti-Venom in 2023
3.2 Global Anti-Venom Revenue by Manufacturers
3.2.1 Global Anti-Venom Revenue by Manufacturers (2019-2024)
3.2.2 Global Anti-Venom Revenue 麻豆原创 Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by Anti-Venom Revenue in 2023
3.3 Global Key Players of Anti-Venom, Industry Ranking, 2022 VS 2023 VS 2024
3.4 Global Anti-Venom Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers 麻豆原创 Concentration Ratio (CR5 and HHI)
3.5.2 Global Anti-Venom 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Anti-Venom, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Anti-Venom, Product Offered and Application
3.8 Global Key Manufacturers of Anti-Venom, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 麻豆原创 Size by Type
4.1 Global Anti-Venom Sales by Type
4.1.1 Global Anti-Venom Historical Sales by Type (2019-2024)
4.1.2 Global Anti-Venom Forecasted Sales by Type (2025-2030)
4.1.3 Global Anti-Venom Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Anti-Venom Revenue by Type
4.2.1 Global Anti-Venom Historical Revenue by Type (2019-2024)
4.2.2 Global Anti-Venom Forecasted Revenue by Type (2025-2030)
4.2.3 Global Anti-Venom Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Anti-Venom Price by Type
4.3.1 Global Anti-Venom Price by Type (2019-2024)
4.3.2 Global Anti-Venom Price Forecast by Type (2025-2030)
5 麻豆原创 Size by Application
5.1 Global Anti-Venom Sales by Application
5.1.1 Global Anti-Venom Historical Sales by Application (2019-2024)
5.1.2 Global Anti-Venom Forecasted Sales by Application (2025-2030)
5.1.3 Global Anti-Venom Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Anti-Venom Revenue by Application
5.2.1 Global Anti-Venom Historical Revenue by Application (2019-2024)
5.2.2 Global Anti-Venom Forecasted Revenue by Application (2025-2030)
5.2.3 Global Anti-Venom Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Anti-Venom Price by Application
5.3.1 Global Anti-Venom Price by Application (2019-2024)
5.3.2 Global Anti-Venom Price Forecast by Application (2025-2030)
6 US & Canada
6.1 US & Canada Anti-Venom 麻豆原创 Size by Type
6.1.1 US & Canada Anti-Venom Sales by Type (2019-2030)
6.1.2 US & Canada Anti-Venom Revenue by Type (2019-2030)
6.2 US & Canada Anti-Venom 麻豆原创 Size by Application
6.2.1 US & Canada Anti-Venom Sales by Application (2019-2030)
6.2.2 US & Canada Anti-Venom Revenue by Application (2019-2030)
6.3 US & Canada Anti-Venom 麻豆原创 Size by Country
6.3.1 US & Canada Anti-Venom Revenue by Country: 2019 VS 2023 VS 2030
6.3.2 US & Canada Anti-Venom Sales by Country (2019-2030)
6.3.3 US & Canada Anti-Venom Revenue by Country (2019-2030)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Anti-Venom 麻豆原创 Size by Type
7.1.1 Europe Anti-Venom Sales by Type (2019-2030)
7.1.2 Europe Anti-Venom Revenue by Type (2019-2030)
7.2 Europe Anti-Venom 麻豆原创 Size by Application
7.2.1 Europe Anti-Venom Sales by Application (2019-2030)
7.2.2 Europe Anti-Venom Revenue by Application (2019-2030)
7.3 Europe Anti-Venom 麻豆原创 Size by Country
7.3.1 Europe Anti-Venom Revenue by Country: 2019 VS 2023 VS 2030
7.3.2 Europe Anti-Venom Sales by Country (2019-2030)
7.3.3 Europe Anti-Venom Revenue by Country (2019-2030)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Anti-Venom 麻豆原创 Size
8.1.1 China Anti-Venom Sales (2019-2030)
8.1.2 China Anti-Venom Revenue (2019-2030)
8.2 China Anti-Venom 麻豆原创 Size by Application
8.2.1 China Anti-Venom Sales by Application (2019-2030)
8.2.2 China Anti-Venom Revenue by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Anti-Venom 麻豆原创 Size by Type
9.1.1 Asia Anti-Venom Sales by Type (2019-2030)
9.1.2 Asia Anti-Venom Revenue by Type (2019-2030)
9.2 Asia Anti-Venom 麻豆原创 Size by Application
9.2.1 Asia Anti-Venom Sales by Application (2019-2030)
9.2.2 Asia Anti-Venom Revenue by Application (2019-2030)
9.3 Asia Anti-Venom Sales by Region
9.3.1 Asia Anti-Venom Revenue by Region: 2019 VS 2023 VS 2030
9.3.2 Asia Anti-Venom Revenue by Region (2019-2030)
9.3.3 Asia Anti-Venom Sales by Region (2019-2030)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Anti-Venom 麻豆原创 Size by Type
10.1.1 Middle East, Africa and Latin America Anti-Venom Sales by Type (2019-2030)
10.1.2 Middle East, Africa and Latin America Anti-Venom Revenue by Type (2019-2030)
10.2 Middle East, Africa and Latin America Anti-Venom 麻豆原创 Size by Application
10.2.1 Middle East, Africa and Latin America Anti-Venom Sales by Application (2019-2030)
10.2.2 Middle East, Africa and Latin America Anti-Venom Revenue by Application (2019-2030)
10.3 Middle East, Africa and Latin America Anti-Venom Sales by Country
10.3.1 Middle East, Africa and Latin America Anti-Venom Revenue by Country: 2019 VS 2023 VS 2030
10.3.2 Middle East, Africa and Latin America Anti-Venom Revenue by Country (2019-2030)
10.3.3 Middle East, Africa and Latin America Anti-Venom Sales by Country (2019-2030)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 CSL
11.1.1 CSL Company Information
11.1.2 CSL Overview
11.1.3 CSL Anti-Venom Sales, Price, Revenue and Gross Margin (2019-2024)
11.1.4 CSL Anti-Venom Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 CSL Recent Developments
11.2 Merck
11.2.1 Merck Company Information
11.2.2 Merck Overview
11.2.3 Merck Anti-Venom Sales, Price, Revenue and Gross Margin (2019-2024)
11.2.4 Merck Anti-Venom Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Merck Recent Developments
11.3 BTG
11.3.1 BTG Company Information
11.3.2 BTG Overview
11.3.3 BTG Anti-Venom Sales, Price, Revenue and Gross Margin (2019-2024)
11.3.4 BTG Anti-Venom Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 BTG Recent Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer Overview
11.4.3 Pfizer Anti-Venom Sales, Price, Revenue and Gross Margin (2019-2024)
11.4.4 Pfizer Anti-Venom Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Pfizer Recent Developments
11.5 Haffkine Bio-Pharmaceutical
11.5.1 Haffkine Bio-Pharmaceutical Company Information
11.5.2 Haffkine Bio-Pharmaceutical Overview
11.5.3 Haffkine Bio-Pharmaceutical Anti-Venom Sales, Price, Revenue and Gross Margin (2019-2024)
11.5.4 Haffkine Bio-Pharmaceutical Anti-Venom Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Haffkine Bio-Pharmaceutical Recent Developments
11.6 Rare Disease Therapeutics
11.6.1 Rare Disease Therapeutics Company Information
11.6.2 Rare Disease Therapeutics Overview
11.6.3 Rare Disease Therapeutics Anti-Venom Sales, Price, Revenue and Gross Margin (2019-2024)
11.6.4 Rare Disease Therapeutics Anti-Venom Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Rare Disease Therapeutics Recent Developments
11.7 Flynn Pharma
11.7.1 Flynn Pharma Company Information
11.7.2 Flynn Pharma Overview
11.7.3 Flynn Pharma Anti-Venom Sales, Price, Revenue and Gross Margin (2019-2024)
11.7.4 Flynn Pharma Anti-Venom Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Flynn Pharma Recent Developments
11.8 Vins Bioproducts
11.8.1 Vins Bioproducts Company Information
11.8.2 Vins Bioproducts Overview
11.8.3 Vins Bioproducts Anti-Venom Sales, Price, Revenue and Gross Margin (2019-2024)
11.8.4 Vins Bioproducts Anti-Venom Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Vins Bioproducts Recent Developments
11.9 Bharat Serums and Vaccines
11.9.1 Bharat Serums and Vaccines Company Information
11.9.2 Bharat Serums and Vaccines Overview
11.9.3 Bharat Serums and Vaccines Anti-Venom Sales, Price, Revenue and Gross Margin (2019-2024)
11.9.4 Bharat Serums and Vaccines Anti-Venom Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Bharat Serums and Vaccines Recent Developments
11.10 Serum Biotech
11.10.1 Serum Biotech Company Information
11.10.2 Serum Biotech Overview
11.10.3 Serum Biotech Anti-Venom Sales, Price, Revenue and Gross Margin (2019-2024)
11.10.4 Serum Biotech Anti-Venom Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Serum Biotech Recent Developments
11.11 MicroPharm
11.11.1 MicroPharm Company Information
11.11.2 MicroPharm Overview
11.11.3 MicroPharm Anti-Venom Sales, Price, Revenue and Gross Margin (2019-2024)
11.11.4 MicroPharm Anti-Venom Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 MicroPharm Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Anti-Venom Industry Chain Analysis
12.2 Anti-Venom Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Anti-Venom Production Mode & Process
12.4 Anti-Venom Sales and 麻豆原创ing
12.4.1 Anti-Venom Sales Channels
12.4.2 Anti-Venom Distributors
12.5 Anti-Venom Customers
13 麻豆原创 Dynamics
13.1 Anti-Venom Industry Trends
13.2 Anti-Venom 麻豆原创 Drivers
13.3 Anti-Venom 麻豆原创 Challenges
13.4 Anti-Venom 麻豆原创 Restraints
14 Key Findings in The Global Anti-Venom Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm
听
听
*If Applicable.